Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: A phase II study

Li Kun Chen, He Huang, Hai Liao, Guo Zhen Liu, Yin Duo Zeng, Xiao Xiao Dinglin, Guang Chuan Xu, Wei Dong Wei

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

To study the treatment outcomes of brain-only metastases from small-cell lung cancer (SCLC) at initial diagnose treated by chemotherapy with concurrent brain and thoracic radiotherapy (RT). From Jan 2004 to Jan 2009, 36 treatment-naïve SCLC patients with brain-only metastases in Sun yat-sen University were enrolled. Treatment contained initial EP chemotherapy with concurrent whole-brain radiotherapy (WBRT). EP regimen consisted of etoposide 100 mg/m2 IV d1-3, cisplatin 80 mg/m2 IV d1, repeated every 3 weeks. WBRT with total dose of 30 Gy in 10 fractions was started within 1 week from the beginning of chemotherapy followed by thoracic RT including 2 Gy once daily to a total dose of 60 Gy. Treatment responses were evaluated after 3 cycles of chemotherapy. EP regimen was given totally 6 cycles for no tumor progression. Thirty-four patients were evaluable. All of the 20 CNS symptomatic patients experienced symptoms relief. Objective responses in the brain and primary thoracic lesions were observed in 26 (76.5%, 16CR + 10PR) and 29 (85.3%, 23CR + 6PR) patients, respectively. The median survival time (MST) was 19.2 months, and the 1-and 2-year overall survival rates (OS) were 70.6 and 29.4%, respectively, in all patients. Patients with CR response had the longest MST of 21.9 months and 1-and 2-year OS of 93.8 and 43.8%, respectively. Treatment toxicity profiles were acceptable. The treatment strategy of concurrent chemotherapy with brain and thoracic RT might achieve promising survival outcomes comparable to limited-stage SCLC in initially diagnosed SCLC with brain-only metastases.

Original languageEnglish (US)
Pages (from-to)1687-1692
Number of pages6
JournalMedical Oncology
Volume29
Issue number3
DOIs
StatePublished - Sep 1 2012

Fingerprint

Small Cell Lung Carcinoma
Radiotherapy
Thorax
Neoplasm Metastasis
Drug Therapy
Brain
Therapeutics
Survival
Survival Rate
Solar System
Etoposide
Brain Neoplasms
Cisplatin
Neoplasms

Keywords

  • Brain metastases (BM)
  • Chemotherapy
  • Small-cell lung cancer (SCLC)
  • Thoracic radiotherapy
  • Whole-brain radiotherapy (WBRT)

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer : A phase II study. / Chen, Li Kun; Huang, He; Liao, Hai; Liu, Guo Zhen; Zeng, Yin Duo; Dinglin, Xiao Xiao; Xu, Guang Chuan; Wei, Wei Dong.

In: Medical Oncology, Vol. 29, No. 3, 01.09.2012, p. 1687-1692.

Research output: Contribution to journalArticle

Chen, Li Kun ; Huang, He ; Liao, Hai ; Liu, Guo Zhen ; Zeng, Yin Duo ; Dinglin, Xiao Xiao ; Xu, Guang Chuan ; Wei, Wei Dong. / Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer : A phase II study. In: Medical Oncology. 2012 ; Vol. 29, No. 3. pp. 1687-1692.
@article{da86461b91fc48c5b5bfa93b3fa03dc7,
title = "Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer: A phase II study",
abstract = "To study the treatment outcomes of brain-only metastases from small-cell lung cancer (SCLC) at initial diagnose treated by chemotherapy with concurrent brain and thoracic radiotherapy (RT). From Jan 2004 to Jan 2009, 36 treatment-na{\"i}ve SCLC patients with brain-only metastases in Sun yat-sen University were enrolled. Treatment contained initial EP chemotherapy with concurrent whole-brain radiotherapy (WBRT). EP regimen consisted of etoposide 100 mg/m2 IV d1-3, cisplatin 80 mg/m2 IV d1, repeated every 3 weeks. WBRT with total dose of 30 Gy in 10 fractions was started within 1 week from the beginning of chemotherapy followed by thoracic RT including 2 Gy once daily to a total dose of 60 Gy. Treatment responses were evaluated after 3 cycles of chemotherapy. EP regimen was given totally 6 cycles for no tumor progression. Thirty-four patients were evaluable. All of the 20 CNS symptomatic patients experienced symptoms relief. Objective responses in the brain and primary thoracic lesions were observed in 26 (76.5{\%}, 16CR + 10PR) and 29 (85.3{\%}, 23CR + 6PR) patients, respectively. The median survival time (MST) was 19.2 months, and the 1-and 2-year overall survival rates (OS) were 70.6 and 29.4{\%}, respectively, in all patients. Patients with CR response had the longest MST of 21.9 months and 1-and 2-year OS of 93.8 and 43.8{\%}, respectively. Treatment toxicity profiles were acceptable. The treatment strategy of concurrent chemotherapy with brain and thoracic RT might achieve promising survival outcomes comparable to limited-stage SCLC in initially diagnosed SCLC with brain-only metastases.",
keywords = "Brain metastases (BM), Chemotherapy, Small-cell lung cancer (SCLC), Thoracic radiotherapy, Whole-brain radiotherapy (WBRT)",
author = "Chen, {Li Kun} and He Huang and Hai Liao and Liu, {Guo Zhen} and Zeng, {Yin Duo} and Dinglin, {Xiao Xiao} and Xu, {Guang Chuan} and Wei, {Wei Dong}",
year = "2012",
month = "9",
day = "1",
doi = "10.1007/s12032-011-0040-8",
language = "English (US)",
volume = "29",
pages = "1687--1692",
journal = "Medical Oncology",
issn = "1357-0560",
publisher = "Humana Press",
number = "3",

}

TY - JOUR

T1 - Chemotherapy with concurrent brain and thoracic radiotherapy in brain-only metastases of treatment naive small-cell lung cancer

T2 - A phase II study

AU - Chen, Li Kun

AU - Huang, He

AU - Liao, Hai

AU - Liu, Guo Zhen

AU - Zeng, Yin Duo

AU - Dinglin, Xiao Xiao

AU - Xu, Guang Chuan

AU - Wei, Wei Dong

PY - 2012/9/1

Y1 - 2012/9/1

N2 - To study the treatment outcomes of brain-only metastases from small-cell lung cancer (SCLC) at initial diagnose treated by chemotherapy with concurrent brain and thoracic radiotherapy (RT). From Jan 2004 to Jan 2009, 36 treatment-naïve SCLC patients with brain-only metastases in Sun yat-sen University were enrolled. Treatment contained initial EP chemotherapy with concurrent whole-brain radiotherapy (WBRT). EP regimen consisted of etoposide 100 mg/m2 IV d1-3, cisplatin 80 mg/m2 IV d1, repeated every 3 weeks. WBRT with total dose of 30 Gy in 10 fractions was started within 1 week from the beginning of chemotherapy followed by thoracic RT including 2 Gy once daily to a total dose of 60 Gy. Treatment responses were evaluated after 3 cycles of chemotherapy. EP regimen was given totally 6 cycles for no tumor progression. Thirty-four patients were evaluable. All of the 20 CNS symptomatic patients experienced symptoms relief. Objective responses in the brain and primary thoracic lesions were observed in 26 (76.5%, 16CR + 10PR) and 29 (85.3%, 23CR + 6PR) patients, respectively. The median survival time (MST) was 19.2 months, and the 1-and 2-year overall survival rates (OS) were 70.6 and 29.4%, respectively, in all patients. Patients with CR response had the longest MST of 21.9 months and 1-and 2-year OS of 93.8 and 43.8%, respectively. Treatment toxicity profiles were acceptable. The treatment strategy of concurrent chemotherapy with brain and thoracic RT might achieve promising survival outcomes comparable to limited-stage SCLC in initially diagnosed SCLC with brain-only metastases.

AB - To study the treatment outcomes of brain-only metastases from small-cell lung cancer (SCLC) at initial diagnose treated by chemotherapy with concurrent brain and thoracic radiotherapy (RT). From Jan 2004 to Jan 2009, 36 treatment-naïve SCLC patients with brain-only metastases in Sun yat-sen University were enrolled. Treatment contained initial EP chemotherapy with concurrent whole-brain radiotherapy (WBRT). EP regimen consisted of etoposide 100 mg/m2 IV d1-3, cisplatin 80 mg/m2 IV d1, repeated every 3 weeks. WBRT with total dose of 30 Gy in 10 fractions was started within 1 week from the beginning of chemotherapy followed by thoracic RT including 2 Gy once daily to a total dose of 60 Gy. Treatment responses were evaluated after 3 cycles of chemotherapy. EP regimen was given totally 6 cycles for no tumor progression. Thirty-four patients were evaluable. All of the 20 CNS symptomatic patients experienced symptoms relief. Objective responses in the brain and primary thoracic lesions were observed in 26 (76.5%, 16CR + 10PR) and 29 (85.3%, 23CR + 6PR) patients, respectively. The median survival time (MST) was 19.2 months, and the 1-and 2-year overall survival rates (OS) were 70.6 and 29.4%, respectively, in all patients. Patients with CR response had the longest MST of 21.9 months and 1-and 2-year OS of 93.8 and 43.8%, respectively. Treatment toxicity profiles were acceptable. The treatment strategy of concurrent chemotherapy with brain and thoracic RT might achieve promising survival outcomes comparable to limited-stage SCLC in initially diagnosed SCLC with brain-only metastases.

KW - Brain metastases (BM)

KW - Chemotherapy

KW - Small-cell lung cancer (SCLC)

KW - Thoracic radiotherapy

KW - Whole-brain radiotherapy (WBRT)

UR - http://www.scopus.com/inward/record.url?scp=84872807030&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872807030&partnerID=8YFLogxK

U2 - 10.1007/s12032-011-0040-8

DO - 10.1007/s12032-011-0040-8

M3 - Article

C2 - 21853344

AN - SCOPUS:84872807030

VL - 29

SP - 1687

EP - 1692

JO - Medical Oncology

JF - Medical Oncology

SN - 1357-0560

IS - 3

ER -